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Abstract
A novel bio-photonics approach based on the nonlinear optical process of second harmonic
generation by non-centrosymmetric nanoparticles is presented and demonstrated on malignant
human cell lines. The proposed method allows to directly interact with DNA in absence of
photosensitizing molecules, to enable independent imaging and therapeutic modalities switch-
ing between the two modes of operation by simply tuning the excitation laser wavelength, and
to avoid any risk of spontaneous activation by any natural or artificial light source.
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We demonstrate here a novel diagnostic and therapeutic (theranostic) protocol based on the
nonlinear optical process of non phase-matched second harmonic (SH) generation by non-centrosymmetric
nanoparticles, referred to in the following as harmonic nanoparticles (HNPs).1,2 To date, the ca-
pability of these recently introduced nanometric probes of doubling any incoming frequency has
not been employed for therapeutic use, although it presents several straightforward advantages,
including i) the possibility to directly interact with DNA of malignant cells in absence of photo-
sensitizing molecules, ii) fully independent access to imaging and therapeutic modalities, and iii)
complete absence of risk of spontaneous activation by natural or artificial light sources other than
pulsed femtosecond lasers. Given the unconstrained tunability of the HNPs nonlinear conversion
process, this approach can be extended to selectively photo-activate molecules at the surface or in
the vicinity of HNPs to further diversify the prospective therapeutic action.3 Here we show that
by tuning the frequency of ultrashort laser pulses from infrared (IR) to visible (both harmless), SH
generation leads respectively to diagnostics (imaging) and therapy (phototoxicity). Specifically,
we report in situ generation of deep ultraviolet (DUV) radiation (270 nm) in human-derived lung
cancer cells treated with bismuth ferrite (BiFeO3, BFO) HNPs upon pulsed laser irradiation in the
visible spectrum, at 540 nm. We observe and quantify the appearance of double-strand breaks
(DSBs) in the DNA and cell apoptosis, in the area of the laser beam. We show that DNA dam-
ages are dependent on irradiation-time, laser intensity, and NP concentration. We observe that
apoptosis and genotoxic effects are only observed when visible light excitation is employed, being
completely absent when IR excitation is used for imaging.
HNPs, a family of NPs specifically conceived for multi-photon imaging, were introduced in
2005 for complementing fluorescence imaging labels.1,4,5 Although comparatively less bright than
quantum dots, HNPs possess a series of advantageous optical properties, including complete ab-
sence of bleaching and blinking,1,6 spectrally narrow emission bands, fully coherent response,7–9
,and UV to IR excitation wavelength tunability.10,11 These unique characteristics have been re-
cently exploited in demanding bio-imaging applications12 including regenerative research.13 The
possibility of working with long wavelengths presents clear advantages in terms of tissue pene-
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Figure 1: Multiphoton imaging of a HNPs treated sample. Lung-derived A549 cancer cells exposed for
5 h to 50 µg/mL BFO HNPs. Yellow: two photon excited fluorescence from cell membrane dye FM1-43FX.
Blue: SH signal from HNPs. Scale bar:10 µm.
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Figure 2: Cytotoxic and oxidative effects of BFO HNPs. The nanomaterial shows good bio-
compatibility with high survival rate after long-term incubation. A: cell survival by MTT for different
exposure times of lung-derived A549 (black bars) and HTB-182 (white bars) cancer cell lines to 100 µg/mL
BFO. B: effect of BFO at 25 and 100 µg/mL on DTT content in an abiotic environment after 1 h of incubation.
C1 and C2: ROS production after 24 h exposure to 25 (white bars) or 100 (black bars) µg/mL HNPs by DHE
(C1) and DCFH-DA (C2) assays. Results statistically compared to untreated cells.
3
tration, as in the IR spectral region, imaging depth is strongly increased by reduced absorption
(provided that water absorption is avoided) and weak scattering (preventing degradation of spatial
and temporal laser profiles).14
As an example of HNPs based imaging, Fig. 1 displays lung-derived A549 cancer cells stained
with FM1-43FX cell membrane dye exposed for 5 h to BFO HNPs at 50 µg/mL. The image was
acquired upon near IR excitation at 790 nm, the two-photon excited fluorescence from the dye
are shown in yellow, while the intense blue spots correspond to SH radiation emitted by HNPs.
The latter have the tendency to remain attached to cell membranes without being internalized due
to their relatively large size. As for other nanobiotechnological approaches, selective binding of
NPs to specific cell membrane receptors would rely on the presence of targeting molecules at their
surface,12 a strategy that was not implemented in this exploratory study.
Given the novelty of the nanomaterial employed in this study, prior to the assessment of photo-
therapeutic modality, BFO HNPs were characterized and screened for biocompatibility in terms
of cytotoxicity and oxidative effect. The cytotoxic effect of 100 µg/mL BFO HNPs was assessed
after 5, 24 and 72 h exposure (Fig. 2A) on two lung-derived cell lines (A549, HTB-182). BFO
cytotoxicity was found acceptable in both samples as HNPs did not cause any detectable effect
on cell survival after 5 h exposure, and after 24 h and 72 h cell viability remains remarkably
high (>75%), comparable to that observed with HNPs composed of other nanomaterials previously
screened.11 To quantify the oxidative stress induced by BFO HNPs, the catalytic activity of the NPs
was first measured in a cell free environment by dithiothreitol (DTT) assay.15 BFO HNPs show a
dose-dependent consumption of DTT after 1 h incubation (Fig. 2B), suggesting that they can exert
catalytic production of superoxide. The production of reactive oxygen species (ROS) by BFO
HNPs in cell cultures was assessed using two fluorescence assays: dihydroethidium (DHE) and
carboxydichlorodihydrofluorescein diacetate (DCFH-DA).16,17 We could detect a dose-dependent
increase of ROS, more pronounced in A549 cells than in HTB-182 (Fig. 2C1 and C2), which
remains however low compared to that induced by other metal-based NPs.11,16–18 Overall, the
result of this thorough screening indicates a good biocompatibility of this nanomaterial, tested for
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the very first time for biological applications, and sets the ground for the light-triggered HNPs-cells
interaction described in the following.
Figure 3: Immunohistochemistry images demonstrating the effect of visible irradiation on malignant
cell lines for apoptosis (cPARP) and DNA repair (γH2AX). Human lung-derived A549 (A) and HTB-182 (B)
cancer cell lines untreated (1) or exposed to 100 µg/mL BFO HNPs (2 and 3), incubated 24 h, and irradiated
for 120 s. Expression of cPARP (2) or γH2AX (3) observed by IHC after further 24 h or 30 min of incubation,
respectively. Positive cells are in brown, nuclei in blue, and HNPs aggregates appear as small brown spots.
Scale bar: 50 µm
DNA absorption is particularly efficient in the deep UV (DUV, <300 nm), as all DNA bases
possess bands peaking around 260 nm with negligible intensity from 310 nm on. Irradiation of
cell cultures at this wavelength results into DSBs and evokes a complex network of molecular
responses, eventually resulting in DNA repair and/or cell apoptosis.19–21 Histone variant H2AX
is a key component of the early stage response to DNA damages, as upon UV exposure it is
phosphorylated at its carboxyl terminus to form γH2AX at the DSBs sites.19,20,22,23 After the first
appearance of UV-induced DNA-damages, cells first activate DNA-repair mechanisms and then
apoptosis occurs to eliminate potentially hazardous cells. UV-dependent apoptosis is caused by the
activation of caspase-3 and subsequently cleavage of the poly (ADP-ribose) polymerase (PARP),
resulting in a cleaved-form (cPARP) with a mass of 89 kDA.23–25 For the irradiation experiment,
cells were plated in 35 mm Petri dishes with glass bottom for 48 h, then medium was replaced
and cells were incubated for 24 h with BFO HNPs (25 or 100 µg/mL, 2 mg/mL stock solution
in water) or a negative control containing the vehicle (distilled water). The sample was exposed
for 30, 60, or 120 s to ultrashort (30 fs) pulses of visible light generated by a noncolliner OPA
(15 mW average power, 1 KHz repetition rate) with a laser spot size of 170 µm diameter. During
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irradiation, cells were kept in a microscope incubator. After light treatment, cells were incubated
for 30 min (γH2AX assay) or 24 h (cPARP detection)22,26,27 and then fixed with 3% formaldehyde
in PBS. Frequency doubling of femtosecond pulses of visible light (540 nm) by HNPs attached to
cell membranes generates DUV photons in the close vicinity of cell nuclei, optimally placed for
direct photo-interaction (see Fig. 1). The biological effects of such laser irradiation is reported
in the immunohistochemistry (IHC) images of Fig. 3. The two image rows are associated to the
two human malignant cell lines already tested for cytotoxicity, A549 and HTB-182. The control
samples (A1, B1) show no expression for both reporters, confirming that they are not present under
physiological conditions, while the clear effect (positive cells in brown) visible in panels 2 and 3
for treated cells indicates that a strong interaction upon irradiation takes places, showing the DNA-
repairing enzyme γH2AX expression well localized within the nuclei and the cPARP reporter of
cell apoptosis in the cytoplasm of the damaged cells.
Figure 4: Spatial localization of the expression of cPARP and γH2AX reporters. Analysis of one rep-
resentative IHC image (480 x 650 µm) for the treatments in Fig. 3. For each rectangular (80 x 130 µm)
sub-region the % ratio of cells positive for the expression of cPARP (column 1) and γH2AX (column 2) is
expressed according to the color-scale. Black empty square: laser spot (150 x 150 µm).
The spatial localization of the IHC expression of the two reporters for DNA repair and cell
apoptosis is given in Fig. 4. The laser focal spot (empty black square) is superimposed to a
spatially resolved pattern of 80× 130µm rectangles indicating in false colors the % of positive
6
cells to cPARP (A1, A2) and γH2AX (B1, B2) for the two cell lines. One can appreciate how the
biological effect of visible irradiation perfectly co-localizes with the laser spot (>80 % positive
cells) and rapidly decreases outside the focal region to negligible values.
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Figure 5: Apoptosis and DNA damage upon visible light exposure. Human lung-derived A549 (A) and
HTB-182 (B) cancer cell lines exposed to vehicle (grey bars) or 100 µg/mL BFO HNPs (black bars), incubated
24 h and irradiated for 30, 60, or 120s. Expression of cPARP (upper row) or γH2AX (lower row) was observed
by IHC after further 24 h or 30 min of incubation, respectively. Results are expressed as % ratio of positive
cells. All comparisons to control or between cells exposed to laser with and without BFO HNPs are significant
(p<0.001) if not otherwise specified.
The quantitative assessment of the effects of in situ DUV generation is reported in Fig. 5. In the
histograms, the number of IHC-positive cells is expressed as % ratio of total cells in the area of the
laser-spot. Firstly, one can observe that BFO HNPs at 100 µg/mL without laser irradiation do not
cause any increase of cPARP and γH2AX expression, ensuring that oxidative effects of BFO alone
do not interfere with irradiation assays. Upon laser-exposure, the ratio of cells positive for cPARP
and γH2AX clearly increases in an exposure time-dependent manner. In A549 the expression of
the two proteins is comparable, whereas HTB-182 express systematically more γH2AX. Such a
stronger enzymatic activity seems correlated with higher cell viability: the maximal expression of
cPARP (apoptosis) is around 60% while in A549 it reaches almost 100%.
The major decrease in cells viability observed upon irradiation of HNPs-treated samples, to-
gether with the high spatial localization of the biological effects, makes HNPs-based approaches
7
amenable for developing therapeutic (photo-dynamic) protocols. With this goal in mind, we per-
formed an additional verification, essential to ensure the possibility of independently addressing
imaging and cell irradiation modalities, ensuring that the definition of the zone to be treated (which
might rely on a specific NPs surface functionalization) can be preliminary safely performed with-
out any risk of unwanted activation. Cells exposed to HNPs were irradiated for 5 min with laser
set at 790 nm (SHG at 395 nm, outside the DNA bases absorption band) with intensity parameters
equal to those of the protocol described above for visible irradiation. In this case, we did not remark
any interference on cells metabolism. As reported in previous works, imaging is not limited to near
infrared wavelengths but it can be performed even above 1.5 µm, with clear advantages in terms of
imaging depth (thanks to decreased scattering and absorption) and long-term photo-stability.1,10
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Figure 6: Effect of laser intensity. Human lung-derived A549 (A) and HTB-182 (B) cancer cell lines exposed
to vehicle (gray bars) or 100 µg/mL BFO HNPs (black bars), incubated 24 h and irradiated for 30, 60 or 120
s. Expression of cPARP (graph at the top) or γH2AX (graph at the bottom) observed by IHC after further 24
h or 30 min of incubation, respectively. Results are expressed as % ratio of positive cells. All comparisons
between cells exposed to laser with and without BFO are significant (p<0.001) if not otherwise specified.
To complete the characterization of the HNPs+visible irradiation sinergistic effects on cells
viability, we further investigated laser intensity and HNP concentration dependence. A549 and
HTB-182 cell lines were exposed to 100 µg/mL HNPs or to vehicle and irradiated with the same
laser average power focused onto a larger surface (400 µm diameter) corresponding to a neat
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Figure 7: Effect of HNPs concentration. Human lung-derived A549 (A) and HTB-182 (B) cancer cell lines
exposed to 25 µg/mL HNPs, incubated 24 h and the irradiated for 30, 60, or 120s. Expression of cPARP
(graph at the top) or γH2AX (graph at the bottom) observed by IHC after further 24 h or 30 min of incubation,
respectively. Results are expressed as % ratio of positive cells. All comparisons to control or between cells
exposed to laser with and without BFO are significant (p<0.001) if not otherwise specified.
fivefold intensity decrease with respect to the previous protocol. As reported in Fig. 6, a substantial
decrease in the expression of both cPARP and γH2AX was detected in the two lung-derived cancer
cell lines. However, the difference between cells treated with BFO and with vehicle remained
always significant, except for the expression of cPARP on HTB-182 cells after 30 s exposure,
suggesting that BFO generate DUV at lower irradiation intensity as well. The greatest difference
between cells exposed to BFO and to vehicle was always observed for the longest exposure and the
decrease on cPARP expression was greater compared to the expression of γH2AX. For assessing
the concentration dependence, A549 and HTB-182 cells were treated with 25 µg/mL of HNPs and
irradiated according to the high intensity protocol. Also in this case, as summarized in Fig. 7,
cells showed a reduced expression of cPARP, which remained anyway always significantly greater
compared to that measured with vehicle. This reduction is more pronounced on HTB-182 cells.
The number of positive cells for γH2AX expression decreased in the two cell lines as well.
The results and controls presented altogether confirm that UV generation and related cytotoxic
and genotoxic effects can be unambiguously ascribed to visible-light excited BFO HNPs. Major
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effects on cell viability (up to 100% apoptosis) are observed in the irradiated areas. The differ-
ence on cPARP expression between cells irradiated with lower laser intensity or exposed to lower
particle concentration suggests that the synergistic effect between laser and HNPs is dominated
by direct DNA photo-damages, but also implies other subsidiary mechanisms, such as a thermal
effects and cell membranes disruption.28–30 The apoptotic cell fraction in samples exposed to 540
nm laser but not treated with HNPs can be ascribed to direct two-photon absorption by DNA, as
previously observed.31,32 Such a non HNP-specific interaction can be easily counteracted thanks
to the fact that the cellular effects exerted by BFO HNPs are limited to the area of the laser spot, as
highlighted in Fig. 4. If IR imaging is preliminary performed to precisely define the zone needing
irradiation, treatment conserves its high specificity. It should be noted that treatment localization
is expected to be greater in the proposed HNP-based approach, which is primarily based on direct
UV absorption by DNA, than in photo-dynamic treatments involving upconverting and plasmonic
NPs. In these two latter cases, NPs-cell interaction is mediated by ROS, which are known to diffuse
through tissues.33,34
In conclusion, we have presented and demonstrated on human-derived cancer cell lines an orig-
inal nano-theranostics approach based on the nonlinear optical properties of HNPs. The method
proposed enables wavelength-selected imaging and direct DUV photo-interaction with nuclear
DNA. The biocompatibility of BFO, a nanomaterial firstly applied here for biological applications,
screened for cytotoxicity and generation of oxidative stress, was found comparable to those of
other HNPs or metal-based nanoparticles currently used in biomedical studies.11,16–18 It should be
noted that all HNPs, possessing high nonlinear efficiency,11 can exert the effects described here,
which are therefore not unique to BFO.
DSBs DNA damages and induction of apoptosis are typical targets of photodynamic therapies,
which normally involved the use of direct UV radiation (with poor tissue penetration and lack of
specificity) or chemical photosensitizers.35,36 To date, NPs-based strategies imply using of organic
sensitizers (with some notable exceptions.37) and are mediated by ROS generation.18,34,38,39 As
for classical phototherapy, these approaches can generate major side effects due to the presence of
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toxic compounds and ROS which can diffuse to nearby tissues generating oxidative stress.40,41 The
approach proposed, based on nonlinear optical response by HNPs and direct photo-interaction with
nuclear DNA, might avoid side effects due to organic ligands and diffusion of toxic compounds,
increasing selectivity and treatment localization. Moreover, the activation of the process is intrin-
sically limited to femtosecond-pulse excitation and cannot be obtained with any other artificial
or natural light source, differently also from the approaches based on sequential up-conversion of
light frequency. This purely physical constrain greatly decreases the risk of unspecific treatment
activation, in particular for surface lesions. Finally, and very notably, the proposed strategy allows
to totally decouple diagnostic modality (IR imaging) from the therapeutic photo-dynamic action
(visible irradiation), by simply tuning the excitation laser wavelength.
Methods
Multi-photon Imaging The imaging set-up is based on a Nikon A1R-MP inverted microscope
coupled with a Spectra-Physics Mai-Tai DeepSee tunable Ti:Sapphire oscillator. A Plan APO 40×
WI N.A. 1.25 objective was used to focus the excitation laser and to epi-collect the nonlinearly
excited signal (SH and membrane dye fluorescence). Four independent non-descanned detectors
acquire in parallel the signal spectrally filtered by four tailored pairs of dichroic mirrors and in-
terference filters (SH filter; 395±5.5, Chroma). Optimal pulse compression at the focal plane was
adjusted by maximizing the SH signal of individual HNPs dispersed on a coverslip.
Visible laser irradiation For visible irradiation, we employed a two-stage non-collinear optical
parametric amplifier (TOPAS White, Light Conversion) set at 540 nm. The output pulse charac-
teristics are: 30 fs pulse duration, 15 mW average power, 1 KHz repetition rate. The sample was
exposed for 30, 60 and 120 s using a laser spot size (measured by a high resolution beam pro-
filer) of 170 µm or 400 µm diameter. During irradiation, cells were kept at controlled temperature
(37oC), CO2 concentration (5%) and humidity in a microscope incubator (Okolab UNO).
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HNPs dispersion and characterization BFO NPs were provided by the German company FEE
at high concentration in ethanol. NPs were diluted 1:50 in 500 mL ethanol and decanted for 10
days. The supernatant was then taken, ethanol evaporated, and NPs re-suspended in distilled water.
Successively, NPs were dispersed by ultra-sonic bath for 24 h and quantified by Prussian blue
assay. For this assay, 50 µL of BFO solution were diluted in 50 µL HCl 6 M and 100 µL of 5%
potassium hexacyanoferrate (Sigma-Aldrich) in PBS were added for 15 min. After incubation, the
solution absorbance was measured at 690 nm in a multiwell-plate reader (Synergy HT, BioTek)
and compared with the absorbance of a calibration curve with known BFO concentration. BFO
NPs were finally diluted at 2 mg/mL in water. DLS and zeta-potential measurements were carried
out with a Malvern NanoZ, yielding: zeta potential -52.7 ± 3.5 mV, mean hydrodynamic diameter
165.3 ± 24 nm.
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